Johns Hopkins University

In December 2014, Compugen announced a multi-year immuno-oncology research collaboration with Johns Hopkins University, under the direction of Drew Pardoll M.D., Ph.D., the Abeloff Professor of Oncology, Medicine, Pathology, and Molecular Biology and Genetics at Johns Hopkins University of Medicine, and Director of the Bloomberg Kimmel Institute for Cancer Immunotherapy at the Sidney Kimmel Cancer Center, and chairman of Compugen’s Scientific Advisory Board. The collaboration focuses on the evaluation of novel T cell and myeloid checkpoint targets identified by Compugen for the potential treatment of cancer. The scope of the collaboration includes identifying differentiating features of Compugen’s novel targets relative to known immuno-oncology targets, and the therapeutic potential of drugs modulating the activity of those novel drugs.


Max 1mb, accepted formats: pdf, doc, docx, rtf
[recaptcha size:compact]
Message Sent. Thank You!